在土耳其人群中冠状动脉疾病患者的固定剂量抗血小板双组治疗:DAPT-TR
Ahmet Öz1, Kenan Toprak2, Ertan Aydin3
1Department of Cardiology, Health Science University, Istanbul Training and Research Hospital, Istanbul - Turquia.
Arquivos brasileiros de cardiologia
|November 28, 2024
概括
固定剂量双抗血小板治疗 (DAPT) 与阿司匹林和克洛皮多格勒是有效和安全的急性和慢性冠状动脉综合征,显示较低的重大心血管不良事件和出血率. 这种DAPT疗法支持冠状动脉综合征患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 双抗血小板治疗 (DAPT) 是冠状动脉综合征的标准,减少死亡率和血栓事件.
- 平衡缺血负担和出血风险是最佳DAPT选择和持续时间的关键.
- 固定剂量组合疗法为DAPT提供了一种标准化的方法.
研究的目的:
- 为了前性地评估固定剂量阿司匹林 (75毫克) + 克洛皮多格雷尔 (75毫克) 治疗的患者的临床结果.
- 评估这个DAPT疗法的安全性和有效性在现实世界中的队列.
- 分析主要不良心血管事件和出血并发症的发生率.
主要方法:
- 这是一项多中心,横截面,观察性队列研究,对1500名急性或慢性冠状动脉综合征患者进行了观察.
- 患者接受固定剂量组合DAPT (阿司匹林75毫克+克洛皮多格雷尔75毫克).
- 主要终点包括住院治疗,心肌梗塞,支架血栓,TVR和出血 (BARC标准);次要终点包括死亡和中风.
主要成果:
- 平均年龄为63岁; 78.5%的人患有急性冠状动脉综合征.
- 心血管住院:7.9%;急性心肌梗塞:2.3%;支架血栓形成:1.3%;目标血管再血管:4.2%.
- 学术研究联盟 (BARC) 的1型出血:3.3%;BARC类型的2,3或5型出血:0.6%. 所有原因的死亡率:0.5%;心血管死亡率:0.3%;中风:0.3%.
结论:
- 固定剂量阿司匹林 (75毫克) + 克洛皮多格雷尔 (75毫克) 联合治疗在治疗急性和慢性冠状动脉综合征方面表现出有效性.
- DAPT疗法显示出良好的安全性,主要心血管不良事件和临床显著出血率较低.
- 这种定剂量DAPT是适当选择的冠状动脉综合征患者的安全有效选择.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
455
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707